Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEO 138559 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis

NCT03514511 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.

NCT NCT03514511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03514511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEO 138559 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis
Lead sponsor
LEO Pharma
Phase
Phase 1
Overall status
Completed
Start date
May 7, 2018
Completion date
March 2, 2021
Enrollment
47 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis